Paul D. Leeson - Concepedia

Author

Paul D. Leeson

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Leeson, Paul D., P D Leeson, P. D. LEESON, P. D. Leeson, P. LEESON, P.D. Leeson, Paul D Leeson, Paul D. Leeson, Paul Leeson, Paul D. Leeson

152

Publications

14.1K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)MSD (UK) Limited (United Kingdom)Loughborough University AstraZeneca (United Kingdom)

About

Paul D. Leeson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	49	5.2K
2	Natural Sciences	25	35	3.1K
3	Engineering	11	13	528
4	Social Sciences	3	3	913
5	Law	1	1	54

Paul D. Leeson

Publications

7.8K

Citations

H-Index

Page 1

	Year	Citations
The Design of Leadlike Combinatorial Libraries Simon J. Teague, A. M. Davis, Paul D. Leeson, Angewandte Chemie International Edition Pharmaceutical ResearchHit IdentificationAffinity EnhancementLeadlike Combinatorial LibrariesMolecular Pharmacology	1999	801
Is There a Difference between Leads and Drugs? A Historical Perspective Tudor I. Oprea, A. M. Davis, Simon J. Teague, Journal of Chemical Information and Computer Sciences	2001	771
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs Mark C. Wenlock, Rupert P. Austin, Patrick Barton, Journal of Medicinal Chemistry Molecular PharmacologyRigorous Selection PressuresPhysiochemical Property ProfilesPharmaceutical SciencePharmacological Study	2003	530
7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. John A. Kemp, Alan C. Foster, Paul D. Leeson, Proceedings of the National Academy of Sciences NeurotransmitterNeurotransmissionCellular PhysiologySocial SciencesSelective Antagonist	1988	520
Time-Related Differences in the Physical Property Profiles of Oral Drugs Paul D. Leeson, A. M. Davis Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyPharmacodynamic ModelingMedicinal ChemistryPharmacological Study	2004	320
Chemical beauty contest Paul D. Leeson Nature Contemporary ArtExperimental AestheticVisual ArtsModel (Person)Chemical Beauty Contest	2012	262
3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine: An Antagonist with High Affinity and Selectivity for the Human Dopamine D<sub>4</sub> Receptor Janusz J. Kulagowski, Howard B. Broughton, Neil R. Curtis, Journal of Medicinal Chemistry Altmetric Attention ScorePsychopharmacologyPharmacotherapySocial SciencesMolecular Pharmacology	1996	257
From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis Brian Springthorpe, A. S. Bailey, Patrick Barton, Bioorganic & Medicinal Chemistry Letters ThrombosisPlatelet Aggregation InhibitorsBiochemistryBlood PlateletMedicine	2007	233
4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor Paul D. Leeson, Robert W. Carling, Kevin W. Moore, Journal of Medicinal Chemistry	1992	187
[ 3 H]L-655,708, a Novel Ligand Selective for the Benzodiazepine Site of GABA A Receptors which Contain the α5 Subunit Kathleen Quirk, Peter Blurton, Stephen R. Fletcher, Neuropharmacology Molecular PharmacologyNovel Ligand SelectiveDrug TargetBiochemistryα5 Subunit	1996	179

Page 1